文献速递消化系统肿瘤妇科肿瘤

卵巢切除在结直肠癌伴卵巢转移及多器官远处转移中的价值

[The value of oophorectomy in colorectal cancer with ovarian metastasis and multiple distant organ metastases].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2025-01-01

该回顾性研究纳入125例结直肠癌伴卵巢转移且多器官远处转移患者,手术组95例(76.0%)与非手术组30例(24.0%)。手术组全身治疗疗效优于非手术组(P<0.001),中位OS为35个月对23个月(P=0.034)。结论认为卵巢切除可延长生存、提高全身治疗疗效并改善生活质量。

要点

  • 卵巢切除组术后全身治疗疗效显著优于非手术组(P<0.001)。
  • 手术组中位OS 35个月,非手术组23个月,差异有统计学意义(P=0.034)。
  • 术后并发症轻微(8.4%),未影响全身治疗实施。

核心结论

  • 在合并多器官远处转移的结直肠癌卵巢转移患者中实施卵巢切除,能提高全身治疗疗效、延长生存时间并提高生活质量。

研究设计与样本

  • 回顾性分析2014年1月至2023年12月中国医学科学院肿瘤医院125例结直肠癌卵巢转移伴多器官远处转移患者的临床病理资料。
  • 按是否行卵巢切除分为手术组95例(76.0%)和非手术组30例(24.0%),对比全身治疗疗效和总生存时间(OS)。

主要发现

  • 手术组95例中8例(8.4%)出现轻微术后并发症,未出现因术后并发症影响全身治疗的情况。
  • 手术组中行术前新辅助治疗者11例(11.6%),术后病理显示卵巢转移瘤治疗反应最差,均呈轻度治疗反应。
  • 手术组术后全身治疗疗效:部分缓解16例(16.8%)、疾病稳定57例(60.0%)、疾病进展3例(3.2%)、无法评估19例(20.0%);非手术组疾病稳定7例(23.3%)、疾病进展23例(76.7%),两组差异有统计学意义(P<0.001)。
  • 全组中位OS为28个月(95% CI:21.5~34.5个月),1、3、5年生存率分别为84.5%、40.7%和23.9%。
  • 手术组中位OS为35个月(95% CI:23.9~46.1个月),1、3、5年生存率分别为87.1%、45.0%和26.4%;非手术组中位OS为23个月(95% CI:16.6~29.4个月),1、3、5年生存率分别为76.2%、27.8%和13.9%;手术组预后优于非手术组(P=0.034)。

临床怎么用

  • 对结直肠癌伴卵巢转移及多器官远处转移患者,可考虑行卵巢切除以改善全身治疗疗效并延长生存。
  • 术前新辅助治疗后卵巢转移瘤治疗反应常较差,术后需关注该部位疗效评估。

局限性

  • 本研究为单中心回顾性分析,样本量有限,结论需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: Exploring the therapeutic value of ovarianectomy in patients with colorectal cancer accompanied by ovarian metastasis and simultaneous multiple organ distant metastasis. Methods: A retrospective analysis was conducted on the clinical pathological data of 125 patients with colorectal cancer and ovarian metastasis accompanied by multiple organ distant metastasis, who were treated at the Cancer Hospital, Chinese Academy of Medical Sciences from January 2014 to December 2023. Based on whether ovarianectomy was performed, patients were divided into a surgical group (95 cases, 76.0%) and a non-surgical group (30 cases, 24.0%). The effectiveness of systemic treatment and overall survival (OS) were compared between the two groups. Results: Among the 95 patients in the surgical group, 8 patients (8.4%) experienced minor postoperative complications, with no instances of systemic treatment being affected by postoperative complications. Within the surgical group, 11 patients (11.6%) underwent preoperative neoadjuvant therapy. Postoperative pathological reports from these patients revealed that ovarian metastases exhibited the poorest treatment response compared to tumor foci in other sites, all demonstrating only mild therapeutic effects. All 95 patients in the surgical group received postoperative systemic treatment (chemotherapy±targeted therapy), and the efficacy was assessed. Among them, 16 patients (16.8%) had partial remission (PR), 57 patients (60.0%) had stable disease (SD), 3 patients (3.2%) had disease progression (PD), and 19 patients (20.0%) could not be evaluated. In the non-surgical group of 30 patients, 7 (23.3%) had SD and 23 (76.7%) had PD. The difference in efficacy between the two groups was statistically significant (P<0.001). The median OS for all patients was 28 months (95% CI: 21.5-34.5), with 1-, 3-, and 5-year survival rates of 84.5%, 40.7%, and 23.9%, respectively. The median OS for patients in the surgical group was 35 months (95% CI: 23.9-46.1), with 1-, 3-, and 5-year survival rates of 87.1%, 45.0%, and 26.4%, respectively. The median OS for patients in the non-surgical group was 23 months (95% CI: 16.6-29.4), with 1-, 3-, and 5-year survival rates of 76.2%, 27.8%, and 13.9%, respectively. The prognosis of patients in the surgical group was significantly better than that in the non-surgical group (P=0.034). Conclusion: Performing ovarianectomy in patients with colorectal cancer and ovarian metastases accompanied by multiple organ distant metastases can prolong survival, improve the efficacy of systemic treatment, and enhance quality of life, resulting in significant overall clinical benefits. 目的: 探讨卵巢切除在结直肠癌伴卵巢转移且同时出现多器官远处转移患者中的治疗价值。 方法: 回顾性分析2014年1月至2023年12月在中国医学科学院肿瘤医院治疗的结直肠癌卵巢转移伴多器官远处转移患者的临床病理资料(125例),根据是否行卵巢切除将患者分为手术组(95例,76.0%)和非手术组(30例,24.0%),对比两组患者的全身治疗疗效和总生存时间(OS)。 结果: 手术组95例患者中,8例(8.4%)出现轻微术后并发症,未出现由于术后并发症影响全身治疗的情况。手术组患者中行术前新辅助治疗者11例(11.6%),这部分患者术后病理报告显示,与其他部位肿瘤灶相比,卵巢转移瘤治疗反应最差,均呈现轻度治疗反应。手术组95例患者均行术后全身治疗(化疗±靶向治疗)并评估疗效,其中部分缓解16例(16.8%),疾病稳定(SD)57例(60.0%),疾病进展(PD)3例(3.2%),无法评估19例(20.0%)。非手术组30例患者中,SD 7例(23.3%),PD 23例(76.7%)。手术组和非手术组之间疗效的差异有统计学意义(P<0.001)。全组患者的中位OS为28个月(95% CI:21.5~34.5个月),1、3、5年生存率分别为84.5%、40.7%和23.9%。手术组患者的中位OS为35个月(95% CI:23.9~46.1个月),1、3、5年生存率分别为87.1%、45.0%和26.4%;非手术组患者的中位OS为23个月(95% CI:16.6~29.4个月),1、3、5年生存率分别为76.2%、27.8%和13.9%。手术组患者的预后优于非手术组(P=0.034)。 结论: 在合并多器官远处转移的结直肠癌卵巢转移患者中实施卵巢切除,能提高患者的全身治疗疗效,延长生存时间,同时可提高生活质量,临床总体获益显著。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang Q, Zhu YL, Dong XS, et al. [The value of oophorectomy in colorectal cancer with ovarian metastasis and multiple distant organ metastases]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 41443742. doi:10.3760/cma.j.cn112152-20250419-00177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。